PMID- 10435723
OWN - NLM
STAT- MEDLINE
DCOM- 19990909
LR  - 20190921
IS  - 0891-6934 (Print)
IS  - 0891-6934 (Linking)
VI  - 30
IP  - 2
DP  - 1999
TI  - Genetic analysis of HLA- and HPA-typing in idiopathic (autoimmune) 
      thrombocytopenic purpura patients treated with cepharanthin.
PG  - 99-105
AB  - We performed genetic analysis of human leukocyte antigen (HLA) and human platelet 
      antigen (HPA) in 45 patients with cepharanthin-treated idiopathic 
      thrombocytopenic purpura. HLA-typing was performed by the polymerase chain 
      reaction-restriction fragment length polymorphism method, and HPA-typing by a 
      polymerase chain reaction-sequence-specific primer method. There were 14 
      responders and 31 nonresponders. Responders included many patients who had 
      already been treated with prednisolone. HLA-DRB1*0901 was significantly more 
      common in responders than in nonresponders. In contrast, HLA-DRB1*0410 and 
      DQB1*0401 were significantly more common in nonresponders. The a/b genotype of 
      HPA-2a/2a (Ko(b)/Ko(b)) was significantly increased in responders. In contrast, 
      HPA-2a/2b (Ko(b)/Ko(a)) and HPA-3a/3b (Bak(a)/Bak(b)) were significantly more 
      common in nonresponders. These findings suggest that genetic studies of HLA and 
      HPA can predict the response of idiopathic thrombocytopenic purpura to 
      cepharanthin.
FAU - Nomura, S
AU  - Nomura S
AD  - The First Department of Internal Medicine, Kansai Medical University, Moriguchi, 
      Osaka, Japan. fwkg4681@mb.infoweb.ne.jp
FAU - Matsuzaki, T
AU  - Matsuzaki T
FAU - Yamaoka, M
AU  - Yamaoka M
FAU - Ozaki, Y
AU  - Ozaki Y
FAU - Nagahama, M
AU  - Nagahama M
FAU - Yoshimura, C
AU  - Yoshimura C
FAU - Kagawa, H
AU  - Kagawa H
FAU - Nakayama, S
AU  - Nakayama S
FAU - Fukuhara, S
AU  - Fukuhara S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Autoimmunity
JT  - Autoimmunity
JID - 8900070
RN  - 0 (2a alloantigen, human)
RN  - 0 (3a alloantigen, human)
RN  - 0 (Alkaloids)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antigens, Human Platelet)
RN  - 0 (Autoantigens)
RN  - 0 (Benzylisoquinolines)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 7592YJ0J6T (cepharanthine)
RN  - 9PHQ9Y1OLM (Prednisolone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alkaloids/pharmacology/*therapeutic use
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Antigens, Human Platelet/*analysis/genetics
MH  - Autoantigens/*genetics/immunology
MH  - Autoimmune Diseases/drug therapy/*genetics/immunology/therapy
MH  - Benzylisoquinolines
MH  - Blood Platelets/immunology
MH  - Combined Modality Therapy
MH  - Drug Resistance/genetics
MH  - Endocytosis/drug effects
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - HLA Antigens/*analysis/genetics
MH  - HLA-DQ Antigens/analysis/genetics
MH  - HLA-DQ beta-Chains
MH  - HLA-DR Antigens/analysis/genetics
MH  - HLA-DRB1 Chains
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Polymerase Chain Reaction
MH  - Polymorphism, Restriction Fragment Length
MH  - Polymorphism, Single-Stranded Conformational
MH  - Prednisolone/therapeutic use
MH  - Purpura, Thrombocytopenic, Idiopathic/drug therapy/*genetics/immunology/therapy
MH  - Splenectomy
MH  - Treatment Outcome
EDAT- 1999/08/06 00:00
MHDA- 1999/08/06 00:01
CRDT- 1999/08/06 00:00
PHST- 1999/08/06 00:00 [pubmed]
PHST- 1999/08/06 00:01 [medline]
PHST- 1999/08/06 00:00 [entrez]
AID - 10.3109/08916939908994767 [doi]
PST - ppublish
SO  - Autoimmunity. 1999;30(2):99-105. doi: 10.3109/08916939908994767.